releases: https://palmer.house.gov/media-center/press-releases/palmer-statement-fda-approval-exondys-51
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://palmer.house.gov/media-center/press-releases/palmer-statement-fda-approval-exondys-51 | Palmer Statement on FDA Approval of Exondys 51 | 2016-09-20 | 2016 | 2016-09 | Republican | House | AL | Gary J. Palmer | P000609 | palmer.house.gov | palmer | https://palmer.house.gov/media-center/press-releases | scraper | September 20, 2016 For Immediate Release Media Contact: Cate Cullen (202)225-4921 Palmer Statement on FDA Approval of Exondys 51 Washington, DC – On Monday, the Food and Drug Administration (FDA) approved a drug for Duchenne muscular dystrophy more than 100 days after the agency’s legally mandated decision date. The drug, Exondys 51 (eteplirsen), is the first of its kind and will benefit patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping. Congressman Gary Palmer (R-AL) offered the following statement: “This was a victory for those affected by Duchenne muscular dystrophy and their families,” said Palmer. “With the FDA approval of Exondys 51, some people impacted by Duchenne have new hope for an improved quality of life and a better tomorrow. I applaud all those who have advocated for this medical advancement, including one of my constituents, Gabe Griffin. While this medical advancement does not treat the cause of Gabe’s muscle degeneration, it is a step in the right direction towards creating and approving the drug that will.” ### | 1 | 2026-03-30T01:40:41Z | 2026-04-08T21:01:54Z |